Clinical Trial Update: PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for SHR-1210 (PD-1 antibody) plus apatinib as first-line treatment in advanced acral melanoma is reported, with the study status c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Apatinib (apatinib)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Melanoma | Phase 2 | Status: UNKNOWN